Timothy Smith, MD
Psychiatry · Philadelphia, PANPI 1508836057
Payments from drug & device makers
Across 76 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$254
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$218
- Axsome Therapeutics, Inc.$161
- Otsuka America Pharmaceutical, Inc.$150
- Lundbeck LLC$138
- Takeda Pharmaceuticals U.S.A., Inc.$113
- plus $322 from 6 others
What the payments were for
- Food & beverage$1,30997%
- Education$473%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 14 | $254 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $218 |
| Axsome Therapeutics, Inc. | 9 | $161 |
| Otsuka America Pharmaceutical, Inc. | 8 | $150 |
| Lundbeck LLC | 8 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $113 |
| Teva Pharmaceuticals USA, Inc. | 7 | $101 |
| Avanir Pharmaceuticals, Inc. | 5 | $78 |
| Acadia Pharmaceuticals Inc | 5 | $62 |
| Sunovion Pharmaceuticals Inc. | 4 | $51 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
How this compares
$1,356 in reported general payments places this provider in the 80th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClozarilClozapine | 26 | $47,879 |
| Quetiapine Fumarate | 118 | $2,810 |
| Memantine Hcl | 13 | $2,725 |
| Aripiprazole | 69 | $2,697 |
| Duloxetine Hcl | 109 | $2,111 |
| Divalproex Sodium | 64 | $1,889 |
| Oxcarbazepine | 33 | $1,820 |
| Fluvoxamine Maleate | 19 | $1,600 |
| Clonazepam | 157 | $1,163 |
| Mirtazapine | 39 | $974 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 53 | $870 |
| Vilazodone Hcl | 11 | $843 |
| Alprazolam ErAlprazolam | 15 | $838 |
| Buspirone Hcl | 38 | $773 |
| Escitalopram Oxalate | 34 | $765 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Philadelphia
- Steven ArnoldPhiladelphia$4.1M
- Michael ThasePhiladelphia$2.2M
- Daniel WeintraubPhiladelphia$647K
- Yvette ShelinePhiladelphia$442K
- Kyle KampmanPhiladelphia$355K
- Christian KohlerPhiladelphia$172K
- Freddy AliPhiladelphia$107K
- Stanley CaroffPhiladelphia$105K
- Richard JaffePhiladelphia$101K
- Ramesh EluriPhiladelphia$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.